Sam Huang
Principal @ Biotechnology Value Fund
San Francisco, United States
Sam Huang is a Principal at BVF Partners L.P., a San Francisco-based private investment firm that invests in biotechnology companies. Sam currently serves as a board observer for Dren Bio. Prior to joining BVF in 2018, he worked with J.P. Morgan’s Healthcare Investment Banking team and co-founded a life-sciences focused MIT alumni angel group. Heholds a B.S. in Chemical Engineering from the Massachusetts Institute of Technology.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Sam Huang invests in
Stages Sam Huang invests in
Countries Sam Huang invests in
Investment Focus
Industry
- Health Care 1 (100%)
- Therapeutics 1 (100%)
- Biotechnology 1 (100%)
- Alternative Medicine 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Nimbus Therapeutics
|
Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinicaldevelopment. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders. | $105M / Venture - Series Unknown / Jul 13, 2021 |
Co-Investors
RA Capital Management
2 deals together
Access Biotechnology
1 deal together
Atlas Venture
1 deal together
Biotechnology Value Fund
1 deal together
Biotechnology Value Fund
1 deal together
Commodore Capital
1 deal together
About Biotechnology Value Fund
Biotechnology Value Fund is a San Francisco-based private investment partnership specializing in fundamentally-driven public biotechnology investments.Since its inception in 1993, BVF has strived to build concentrated, long-term investments in small-cap biotechnology companies while performing rigorous diligence and on-going monitoring of itsinvestments.BVF is committed to working with its portfolio companies as partners in their successes.
Biotechnology Value Fund Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Gorjan Hrustanovic
Managing Director
|
|||
James Kratky
Chief Financial Officer, Chief Compliance Officer
|
|||
Matthew Perry
Portfolio Manager
|
|||
Michael Murray
Managing Director
|
|||
|
Sam Huang
Principal
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Sam Huang invest in?
Sam Huang invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Venture - Series Unknown stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Sam Huang last invest?
The most recent investment recorded for Sam Huang closed in Jul 2021. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
